Eli Lilly and Company has finalized its acquisition of Adverum Biotechnologies, a move that delivers a promising gene therapy platform for ocular diseases to the Indianapolis-based pharmaceutical giant. The transaction, which significantly broadens Lilly’s therapeutic portfolio, was completed just six weeks after its initial announcement, marking an unusually swift execution.
Financial Terms and Transaction Timeline
The tender offer for Adverum expired as scheduled at 11:59 p.m. Eastern Time on December 8. Approximately 64% of the outstanding Adverum shares were tendered, a sufficient threshold to seal the deal. Shareholders are receiving an immediate cash payment of $3.56 per share. This base amount is supplemented by the potential for up to an additional $8.91 per share via Contingent Value Rights (CVRs), which will be paid upon the achievement of specific developmental and regulatory milestones.
This structure brings the total potential value to $12.47 per share. The merger is set to be formally completed on December 9, 2025, following a rapid process that began with the first deal documents in late October.
Strategic Rationale Behind the Deal
Adverum’s core asset is its proprietary intravitreal gene therapy platform, highlighted by the candidate ixoberogene soroparvovec (Ixo-vec). Developed as a one-time injection into the eye, Ixo-vec aims to treat patients with wet age-related macular degeneration (AMD). Current standard treatments often require repeated intraocular injections, a burden a single-administration gene therapy could eliminate.
Andrew Adams, Lilly’s Group Vice President of Molecule Discovery, stated that the acquisition presents an opportunity to extend the potential of gene therapy to age-related conditions, including vision loss. The technology aligns with Lilly’s stated strategy of leveraging biotechnology, chemistry, and genetic medicine to tackle major health challenges.
Should investors sell immediately? Or is it worth buying Eli Lilly?
A Company Operating from a Position of Strength
Lilly executed this acquisition from a robust financial foundation. In Q3 2025, the company reported a 54% surge in revenue, propelled by key products such as its incretin analogs. Its U.S. market share in this segment reached nearly 58%. Furthermore, Lilly raised its full-year revenue guidance by over $2 billion, now projecting $63.0 to $63.5 billion.
In November 2025, Lilly became the first pharmaceutical firm to surpass a $1 trillion market capitalization. Concurrently, the company is making substantial investments in manufacturing capacity, with new facilities in Virginia, Texas, and Puerto Rico, and maintains an extensive partnership network. Its Catalyze360 program currently oversees more than 90 collaborations with over 65 biotech companies.
Recent Regulatory Momentum
Shortly before closing the Adverum deal, Lilly secured further regulatory approvals from the U.S. Food and Drug Administration (FDA). On December 3, Jaypirca (pirtobrutinib) received an expanded indication for adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following prior BTK inhibitor therapy. At the ASH congress (December 9-12), Lilly is presenting Phase 3 data demonstrating that Jaypirca reduced the risk of disease progression by 80% in previously untreated CLL/SLL patients compared to chemoimmunotherapy.
Additionally, the oral GLP-1 pill, orforglipron, is advancing toward commercialization, with an imminent FDA submission that may include a Fast-Track designation.
Forward-Looking Implications
The Adverum acquisition notably expands Lilly’s focus beyond metabolic diseases. Integrating this gene therapy expertise will test whether Ixo-vec can establish a new pillar for the company in ophthalmology. The coming months will feature further data presentations, including results for Inluriyo and Verzenio at the San Antonio Breast Cancer Symposium (December 9-12). For investors, Eli Lilly remains a diversified leader with multiple growth drivers, now fortified with a strategic position in genetic medicine.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from December 9 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 9.
Eli Lilly: Buy or sell? Read more here...
